Annual Report 2018
This page provides a summary of the significant progress we have made in 2018 against our long-term priorities of Innovation, Performance and Trust, underpinned by a continuing shift in culture. The full Annual Report or individual sections can be downloaded below.
GSK at a glance
Our long-term priorities underpinned by our culture
We deliver our long-term priorities through each of our three businesses. They are designed to create long-term value for patients, consumers and shareholders, and are underpinned by our ambition to build a culture with a greater performance focus, aligned to our values and expectations.
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
- Excellent execution of key launches: Trelegy Ellipta, Juluca, and Shingrix
- Strengthen Pharmaceutical pipeline through greater focus, improved medicines development and business development
- Delivered industry-leading launches of Shingrix and Trelegy Ellipta, with strong start to sales of Juluca
- New R&D approach to focus on science of the immune system, human genetics and advanced technologies
- Strengthened pipeline through strategic business development with 23andMe and Tesaro and terminated or divested around 80 programmes to focus investment on most promising assets
- Significant progress in reshaping Pharmaceuticals R&D portfolio, with 33* of 46 new medicines now targeting modulation of the immune system
- Deliver continued strong sales of Trelegy Ellipta, Nucala, HIV two-drug regimen and Shingrix
- Continue to strengthen pipeline through execution of new R&D approach, accelerating priority assets and optimising recent strategic business development transactions
* Includes M7824, the subject of the proposed alliance with Merck KGaA, Darmstadt, Germany, expected to close in Q1 2019.
We deliver growth based performance by investing effectively in our business, developing our people and executing competitively.
- Grow sales in priority therapy areas, categories and markets
- Increase operating margins and deliver improved cash flow
- Strengthen top talent profile in key roles
- Group sales £30.8 billion, up 2% AER, 5% CER, with growth in new respiratory product sales and HIV
- Total Group operating margin 17.8%, up 4.3 percentage points AER, up 5.0 percentage points CER. Adjusted Group operating margin 28.4%, flat AER, up 0.5 percentage points CER
- Net cash flow from operations £8.4 billion, up from £6.9 billion. Free cash flow £5.7 billion, up from £3.5 billion
- Announced transaction to create a world-leading Consumer Healthcare Joint Venture with Pfizer and bought out Novartis’ stake in GSK Consumer Healthcare
- Key leadership appointments in place with 69% of top 125 leaders new in role
- Continue to drive sales growth and operational performance
- Successful integration of Tesaro
- Deliver restructuring benefits and plan for the integration of Pfizer’s consumer healthcare business
- Accelerate capability build in priority areas including digital data and analytics
We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.
- Focus on supply service levels
- Define new global health approach
- Competitive employee engagement
- Established new set of priorities and public commitments to build trust
- Continued to simplify supply chain and improve supply performance
- Received approval for tafenoquine, the first new treatment for P. vivax malaria in 60 years
- Candidate TB vaccine showed positive results in phase IIb trial
- Competitive employee engagement through focus on modern employer
- All employees globally to have access to a preventive healthcare package
- Focus on supply service levels, execute portfolio and network simplification
- Deliver progress on Trust commitments
- Progress global health research in TB and HIV
- Deliver modern employer programmes to empower employees to be themselves, feel good and keep growing at GSK
Please read our cautionary statement regarding forward-looking statements in our 2018 Annual Report.
We use a number of adjusted, non-IFRS, measures to report the performance of our business. Total reported results represent the Group's overall performance under IFRS. Adjusted results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results and other non-IFRS measures are defined on pages 40 to 42 of the Annual Report and reconciliations to the nearest IFRS measures are on pages 51 and 56 of the Annual Report.
We believe that Adjusted results, when considered together with Total results, provide investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allow the Group's performance to be more easily compared against the majority of its peer companies. These measures are also used by management for planning and reporting purposes. They may not be directly comparable with similarly described measures used by other companies.
The information contained on this Annual Report 2018 summary page of gsk.com is a summary of and contains extracts from the GSK Annual Report and Accounts 2018. The summary or extracts alone do not contain sufficient information to allow a full understanding of the results and state of affairs of GlaxoSmithKline PLC or the GSK Group. For further information the GSK Annual Report and Accounts 2018 should be consulted, including the cautionary statement on forward looking statements.
Corporate reporting archive
Archive of Annual Reports and Corporate Responsibility Reports dating back to 2000
Discover our latest financial performance announcement and search for historical quarterly results materials
At GSK we are committed to operating at the highest standards of corporate governance. We believe our governance structure underpins our ability to deliver the Group's strategy to create long-term value and benefit for our shareholders and stakeholders.
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.